ARTICLE | Clinical News
RVSV-EBOV: Phase II/III started
February 23, 2015 8:00 AM UTC
The National Institute of Allergy and Infectious Diseases (NIAID) began the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial to evaluate a single injection of cAd-EBOZ or VSV-ZEB...